■白藜芦醇是广泛存在于植物中的天然酚类化合物。先前的研究表明,由于其抗氧化作用,其在脑缺血中的神经保护作用,抗炎,和抗凋亡作用。白藜芦醇鼻内给药增强其穿透血脑屏障的能力,提高治疗效果和安全性。
■我们旨在研究暴露于脑缺血的大鼠鼻内施用白藜芦醇治疗的治疗潜力。
■64只雄性大鼠分为三组:假手术组,仅暴露于手术压力;载体和白藜芦醇组,大脑中动脉闭塞后,鼻内接受载体或50mg/kg白藜芦醇7天,分别。我们评估了修改后的神经系统严重程度评分,电线悬挂试验,血脑屏障破坏,脑含水量,和梗死体积。基质金属蛋白酶-9,核因子-κB,检查了B细胞淋巴瘤蛋白2和B细胞淋巴瘤蛋白2相关的X信使RNA表达。
■在缺血后3天和7天,与接受媒介物的大鼠相比,接受鼻内白藜芦醇的大鼠具有更低的神经严重程度评分和更小的脑梗塞体积.此外,与媒介物组相比,鼻内白藜芦醇治疗的大鼠在缺血后7天表现出明显延长的挂线性能.白藜芦醇组的血脑屏障破坏和脑含水量显著低于媒介物组。此外,与媒介物组相比,白藜芦醇处理组显示基质金属蛋白酶-9和核因子-κB的表达较低,而B细胞淋巴瘤蛋白2相关X和B细胞淋巴瘤蛋白2的表达水平差异无统计学意义。
■鼻内给药白藜芦醇通过改善神经行为功能对缺血性卒中具有神经保护作用,减少血脑屏障的破坏,脑水肿,和梗死体积。这种治疗也下调基质金属蛋白酶-9和核因子-κB的表达,表明其作为缺血性卒中的治疗选择的潜力。
UNASSIGNED: Resveratrol is a natural phenolic compound widely found in plants. Previous studies have suggested its neuroprotective role in cerebral ischemia due to its anti-oxidative, anti-inflammatory, and anti-apoptotic effects. Intranasal administration of resveratrol enhances its capacity to penetrate the blood-brain barrier, increasing therapeutic efficacy and safety.
UNASSIGNED: We aimed to examine the therapeutic potential of intranasal administration of resveratrol treatment in rats exposed to cerebral ischemia.
UNASSIGNED: Sixty-four male rats were divided into three groups: the sham group, which was exposed to only surgical stress; the vehicle and resveratrol groups, which received intranasal vehicle or 50 mg/kg resveratrol for 7 days following middle cerebral artery occlusion, respectively. We assessed the modified neurologic severity scores, wire hanging tests, blood-brain barrier disruption, brain water content, and infarct volume. Levels of matrix metalloproteinase-9, nuclear factor-kappa B, B-cell lymphoma protein 2, and B-cell lymphoma protein 2-associated X messenger RNA expression were examined.
UNASSIGNED: At 3- and 7-days post-ischemia, rats receiving intranasal resveratrol had lower modified neurological severity scores and a smaller brain infarct volume than the rats receiving vehicle. Additionally, the intranasal resveratrol-treated rats showed significantly prolonged wire-hanging performance at the 7-day mark post-ischemia compared to the vehicle group. The blood-brain barrier disruption and brain water content were significantly lower in the resveratrol group than in the vehicle group. Furthermore, the resveratrol-treated group displayed lower expression of Matrix Metalloproteinase-9 and Nuclear Factor-Kappa B in contrast to the vehicle group, while the difference in expression levels of B-cell lymphoma protein 2-associated X and B-cell lymphoma protein 2 were not significant.
UNASSIGNED: Intranasal administration of resveratrol showed neuroprotective effects on ischemic stroke by improving neurobehavioral function, reducing blood-brain barrier disruption, cerebral edema, and infarct volume. This treatment also downregulated Matrix Metalloproteinase-9 and Nuclear Factor-Kappa B expression, indicating its potential as a therapeutic option for ischemic stroke.